AKLIEF (trifarotene) by Galderma is (rar), with particular activity at the gamma subtype of rar. First approved in 2019.
Drug data last refreshed 9h ago · AI intelligence enriched Yesterday
AKLIEF (trifarotene) is a topical retinoid cream that selectively activates retinoic acid receptor-gamma (RAR-γ) to treat acne. It modulates gene expression related to cell differentiation and inflammation, though the exact mechanism of acne amelioration remains incompletely understood. The drug represents a next-generation retinoid designed for improved tolerability in acne patients.
AKLIEF is at peak commercial maturity with modest Medicare utilization, suggesting a stable but not rapidly expanding commercial footprint.
(RAR), with particular activity at the gamma subtype of RAR. Stimulation of RAR results in modulation of target genes which are associated with various processes, including cell differentiation and mediation of inflammation. The exact process by which trifarotene ameliorates acne is unknown.
Retinoid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris
Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris
AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation
Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation
A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)
Worked on AKLIEF at Galderma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moAKLIEF offers career opportunities in a stable, specialized dermatology product with modest but consistent utilization. Roles focus on commercial optimization and maintaining prescriber relationships rather than growth-stage product launches.